US · Healthcare · Medical Care Facilities
EPS came in at 0.58 against a street estimate of 0.54 — a beat of 7.4%.
Analysts rate Mednax Inc a buy (3 buy, 5 hold, 0 sell out of 8) with an average price target of $26.33.
CONFIDENT Q2 revenue +4% YoY; adjusted EBITDA $76M solid. Volume down 2% (neonatology pressured) but offset by pricing gains: RCM collections, payer mix, acuity. FY26 EBITDA guidance $280–300M reaffirmed. Aggressive on buybacks (7M shares since Aug 2025) and eyeing M&A in women's/children's care. Q2 2026 No geographic breakdown provided. Company operates across 32 states with 170+ MFMs and presence in 360+ NICUs. Analysts pressed on payer mix resilience vs. peers (subsidy cliff), volume trend sustainability, and pricing driver decomposition. Management attributed payer stability to pregnant population retention incentives, volume decline to seasonality, and quantified RCM as primary pricing engine with expected fade in H2. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 16.71% |
| Vanguard Portfolio Management, LLC | 7.57% |
| Dimensional Fund Advisors, Inc. | 5.19% |
| Vanguard Capital Management, LLC | 4.50% |
| Victory Capital Management Inc. | 4.21% |
| State Street Corp | 4.16% |
| Wasatch Advisors LP | 3.08% |
| FMR Inc | 2.79% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 PEDIATRIX MEDICAL GROUP, INC. - 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Net Revenue (6 months): $963,979 thousand ($963.98 | 2026-08-04 |
| Results announced · Q3 2026 PEDIATRIX MEDICAL GROUP – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 EPS: $0.49 per diluted share (GAAP); $0.63 Adjusted EPS (non-GAAP) • Q | 2026-08-04 |
| Board / officer change · Q3 2026 PEDIATRIX MEDICAL GROUP, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company: Pediatrix Medical Group, Inc. (NYSE: MD) • Filing Date: July 24, 2026 • Repor | 2026-07-24 |
| Results announced · Q3 2026 | 2026-07-15 |
| Board / officer change · Q2 2026 PEDIATRIX MEDICAL GROUP, INC. – 8-K SUMMARY HEADLINE NUMBERS • Annual Shareholders' Meeting held May 7, 2026 • 83,072,104 total shares outstanding a | 2026-05-07 |
| Quarterly report · Q1 2026 PEDIATRIX MEDICAL GROUP, INC. – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Net revenue Q1 2026: $476.2 million (up 3.9% vs. Q1 2025: $458.4 millio | 2026-05-05 |
| Proxy statement · Q1 2026 PEDIATRIX MEDICAL GROUP, INC. – 2026 PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Election of 9 Directors: Laura A. Linynsky, Thomas A. McEa | 2026-03-27 |
| Annual report FY2025 PEDIATRIX MEDICAL GROUP, INC. - 10-K SUMMARY HEADLINE NUMBERS • Shares Outstanding: 83,001,072 shares as of February 13, 2026 • Market Capitalizatio | 2026-02-19 |
Readable in the app.
| Announcement | Date |
|---|---|
| Reaffirms full year 2026 Adjusted EBITDA outlook of $280-300 million Pediatrix Medical Group, a physician services company with ~4,300 affiliated clinicians, issued a reassuring Q2 2026 update on July 15, 2026. The company confirmed that despite recent health | 2026-07-15 |
| Raises full year 2025 adjusted EBITDA outlook range Pediatrix Medical Group reported stronger-than-expected third quarter 2025 results and raised its full-year outlook. Key highlights: Q3 earnings of $0.84 per share (adjusted EPS $0.67), net | 2025-11-03 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mednax Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.